IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)Joanne Jones, Alasdair Coles, Maria Ban et al.|Journal of Clinical Investigation|2009Cited by 299
Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple SclerosisJessica L. Davies, Joanne Jones, Sara Thompson et al.|PLoS ONE|2016Cited by 17